Loading...

DSGN - Design Therapeutics, Inc.

Analyst Coverage Initiated Signal for 06-10-2022
Analyst Coverage Initiated: DSGN rating Outperform by Wedbush
Price Target: $21



Stock Signal Information


Signal

Analyst Coverage Initiated Stock
Report Date: 06-10-2022
Symbol: DSGN - Design Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Coverage Initiated: DSGN rating Outperform by Wedbush
Price Target: $21

  DSGN Technical Chart

Company Contact

Design Therapeutics, Inc. (DSGN)
6005 Hidden Valley Road
Carlsbad, CA 92011
Phone: 858 293 4900
Website: https://www.designtx.com
CEO:


Company Profile

Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.